2014, ER and Insurance - Primary Care Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2014

Insurance

Exposure to high-priority drug-drug interactions among non-elderly adults in Quebec: a cohort study [Prescribing and pharmacotherapeutics]

Annals of Family Medicine

NOVEMBER 20, 2024

Dataset: Quebec administrative health databases containing de-identified prescription drug claims, ER visits, hospitalizations, and medical acts held by the National Institute for Excellence in Health and Social Services (INESSS) were used. Outcome measures: 1) yearly prevalence and incidence of exposure to at least one high-priority DDI.

Primary Care

Primary Care Emergency Room Insurance ER

Ding Dong is the Skinny Label (Effectively) Dead?

FDA Law Blog

SEPTEMBER 6, 2021

Briefly (more detail is available here ), GSK sued Teva back in 2014 alleging that Teva induced infringement of a method-of-use patent when Teva marketed a skinny-labeled generic version of GSK’s Coreg (carvedilol) as AB-rated. Instead, it was GSK who erred in omitting the post-MI language from the use code.

IT Provider ER Insurance

Exposure to high-priority drug-drug interactions among non-elderly adults in Quebec: a cohort study [Prescribing and pharmacotherapeutics]

Ding Dong is the Skinny Label (Effectively) Dead?

Stay Connected